Posaconazole oral suspension 40 mg/mL
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fungal Infections
Conditions
Fungal Infections
Trial Timeline
Feb 1, 2012 → Nov 1, 2013
NCT ID
NCT01436578About Posaconazole oral suspension 40 mg/mL
Posaconazole oral suspension 40 mg/mL is a pre-clinical stage product being developed by Merck for Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01436578. Target conditions include Fungal Infections.
What happened to similar drugs?
9 of 20 similar drugs in Fungal Infections were approved
Approved (9) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01436578 | Pre-clinical | Completed |
Competing Products
20 competing products in Fungal Infections